Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | GDC-0587 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on GDC-0587, a putative CDK4 inhibitor (Jan 2026). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| GDC-0587 | GDC0587|GDC 0587|RGT-587|RGT587|RGT 587 | CDK4 Inhibitor 19 | Limited information is currently available on GDC-0587, a putative CDK4 inhibitor (Jan 2026). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07214662 | Phase I | GDC-0587 + Giredestrant GDC-0587 GDC-0587 + Giredestrant + Omeprazole | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer | Recruiting | USA | 0 |